Validus Cellular Therapeutics

Validus Cellular Therapeutics is a biotechnology company developing a first-in-class cell therapy platform to treat severe, drug-resistant bacterial infections. The company's lead candidate, VCT-01, consists of activated, donor-derived granulocytes designed to bolster the patient's innate immune response against pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA). This approach addresses the critical global health threat of antimicrobial resistance by using cellular mechanisms rather than traditional small-molecule antibiotics. Validus is a portfolio company of Velocity Pharmaceutical Development and is currently in the pre-clinical stage of development, focusing on indications like bacteremia and soft tissue infections.